Nazli GÜLSOY KIRNAP, Yusuf BOSKUŞ, Cüneyd ANIL

Graves’ disease does not pose an increased risk of thyroid cancer

Aim: The information on increased cancer risk in thyroid nodules in the background of Graves’ disease (GD) is rarely published. In GD,thyroid stimulating hormone (TSH) and TSH receptor antibody (TRAB) are held responsible for playing the key role in the enlargementof nodules and carcinogenesis. In this study, our aim was to evaluate the relationship between GD and thyroid nodules and whetherGD increases the risk of thyroid cancer.Material and Methods: TAll patients diagnosed with GD were evaluated for TRAB, anti-thyroidperoxidase (anti-TPO), antithyroglobulin (anti-TG), and with thyroid function tests (TSH, sT3, sT4), and thyroid ultrasonography. Fine needle aspiration (FNA)biopsy was performed on the suitable thyroid nodules.Results: Archived records of 182 cases followed-up with the diagnosis of GD between 2008-2014 were evaluated retrospectively.Thyroid nodules were found in 38% (n=69) of the cases. The results of the FNA biopsy of 22 of the 26 (30.5%) nodules of a total of85 nodules were benign, and 4 were indeterminate. Thyroidectomy was performed on 4 cases with indeterminate results and theirpathology results revealed that the nodules were benign. In one case operated due to unresponsiveness to medical treatment,papillary thyroid carcinoma (PTC) was detected. No correlation was detected between TRAB positivity and nodule presence andnodule cytology.Conclusion: In the background of GD, increased nodule prevalence, increased cancer risk in nodules, and the concern for poorprognosis, which have been a matter of debate in the recent years, were not confirmed in our study. We recommend the conventionalapproach to thyroid nodules in the background of GD.

PDF

___

1. Bahn Chair RS, Burch HB, Cooper DS et al. American Thyroid Association; American Association of Clinical Endocrinologists.Hyperthyroidism and other causes of thyrotoxicosis: managementg uidelines of theAmerican Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593-646.
2. Dobyns BM, Sheline GE, Workman JB et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974;38:976-98.
3. Pacini F, Elisei R, DiCoscio GC et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest 1988;11:107-12.
4. Brander A, Viikinkoski P, Nickels J et al. Thyroidgland: US screening in a random adult population. Radiology 1991;181:683-7.
5. Bruneton JN, Balu-Maestro C, Marcy PY, et al. Very high frequency(13 MHz) ultrasonographic examination of the normal neck: detection of normal lymph nodes and thyroid nodules. J Ultrasound Med 1994;13:87- 90.
6. Shapiro SJ, Friedman NB, Perzik SL et al. Incidence of thyroid carcinoma in Graves’ disease. Cancer 1970;26:1261-70.
7. Rieger R, Pimpl W, Money S et al. Hyperthyroidism and concurrent thyroid malignancies.Surgery 1989;106:6- 10.
8. Filetti S, Belfiore A, Amir SM et al.The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med 1988;318:753-9.
9. Clark OH, Castner BJ. Thyrotropin “receptors” in normal and neoplastic human thyroid tissue. Surgery 1979;85:624-32.
10. Abe Y, Ichikawa Y, Muraki T, Ito K, Homma M. Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab 1981;52:23-8.
11. Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. EndocrRev 1988;9:106-21.
12. Miller M, Chodos RB. Thyroid carcinoma occurring in Graves’ disease. ArchIntern Med 1966;117:432-5.
13. Belfiore A, Russo D, Vigneri R, et al. Graves’ disease, thyroid nodules And thyroid cancer. Clin Endocrinol (Oxf) 2001;55:711-8.
14. Carnell NE, Valente WA. Thyroidnodules in Graves’ disease: classification, characterization, and response to treatment. Thyroid 1998;8:571-6.
15. Haugen BR, Alexander EK, Bible KC, et al. 2015 AmericanThyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
16. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31.
17. Guth S, Theune U, Aberle J et al.Very high prevalence of Thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009;39:699-706.
18. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537-40.
19. Hegedüs L. Clinicalpractice. Thethyroidnodule. N Engl J Med 2004;351:1764-71.
20. Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev 1988;9:106-21.
21. Kwong N, Medici M, Angell TE et al. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab 2015;100:4434-40.
22. Kraimps JL, Bouin-Pineau MH, Mathonnet M, et al. Multicentre study of thyroid nodules in patients with Graves’ disease. Br J Surg 2000;87:1111-3.
23. Belfiore A, Garofalo MR, Giuffrida D et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990;70:830- 5.
24. Medas F, Erdas E, Canu GL et al. Does Hyperthyroidism worsen prognosis of thyroidcarcinoma? A retrospective analysis on 2820 consecutive thyroidectomies. J Otolaryngol Head NeckSurg 2018;22:47:6.
25. Menon R, Nair CG, Babu M et al. The Outcome of Papillary Thyroid Cancer Associated with Graves’ Disease: A Case Control Study. J Thyroid Res 2018;8:8253094.
26. Yano Y, Shibuya H, Kitagawa W et al. Recentoutcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol 2007;157:325-9 Ann Med Res 2019;26(11):2553-6 25